Skip to main content
SpringerLink
Log in

The Role of Hyperthermic Intraperitoneal Chemotherapy Using Paclitaxel in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer Patients with Microscopic Residual Disease after Cytoreduction

  • Gynecologic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

We analyzed the role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) on the microscopic component of the disease in patients with a first recurrence of platinum-sensitive ovarian cancer after complete cytoreduction (CCR).

Patients and Methods

We analyzed the data of 54 patients who were operated on between January 2001 and July 2012 with the diagnosis of platinum-sensitive recurrent ovarian cancer. In all patients, it was possible to achieve a CCR. Patients were divided into two groups: group I (cytoreduction alone) consisted of 22 surgical patients and group II (cytoreduction and HIPEC) consisted of 32 patients.

Results

There were no significant differences in any of the preoperative variables studied. After a multivariate analysis of factors identified in the univariate analysis, only the presence of tumors with undifferentiated histology (hazard ratio 2.57; 95 % CI 1.21–5.46; p < 0.05) was an independent factor associated with a reduced disease-free survival. The 1- and 3-year disease-free survival was 77 and 23 % in patients from group I and 77 and 45 % in patients from group II, respectively, with a tendency, but no significant differences (p = 0.078). There was no significant difference in postoperative morbidity between the two groups.

Conclusions

The administration of HIPEC in patients in whom it is possible to achieve a CCR of the disease has not increased postoperative morbidity and mortality rates in our center. HIPEC with paclitaxel is effective in the treatment of microscopic disease in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction, although with no statistically significant difference.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–2.

    Article  PubMed  Google Scholar 

  2. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374:1371–82.

    Article  CAS  PubMed  Google Scholar 

  3. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.

    Article  PubMed  Google Scholar 

  4. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.

    Article  CAS  PubMed  Google Scholar 

  5. Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26–31.

    Article  PubMed  Google Scholar 

  6. Rubin SC, Hoskins WJ, Hakes TB, et al. Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors. Am J Obstet Gynecol. 1988;159:1094–8.

    Article  CAS  PubMed  Google Scholar 

  7. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–200.

    Article  CAS  PubMed  Google Scholar 

  8. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374:1371–82.

    Article  CAS  PubMed  Google Scholar 

  9. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol. 2004;95:273.

    Article  CAS  PubMed  Google Scholar 

  10. Güngör M, Ortaç F, Arvas M, et al. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol. 2005;97:74.

    Article  PubMed  Google Scholar 

  11. Onda T, Yoshikawa H, Yasugi T, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer. 2005;92:1026.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Berek JS, Bertelsen K, du Bois A, et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol. 1999;10 Suppl 1:87.

    Article  PubMed  Google Scholar 

  13. Salani R, Santillan A, Zahurak ML, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007;109:685.

    Article  PubMed  Google Scholar 

  14. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106:1933.

    Article  PubMed  Google Scholar 

  15. Sugarbaker PH. It’s what the surgeon doesn’t see that kills the patient. J Nippon Med Sch. 2000;67:5–8.

    Article  CAS  PubMed  Google Scholar 

  16. Sugarbaker PH. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer. Curr Opin Obstet Gynecol. 2009;21:15–24.

    Article  PubMed  Google Scholar 

  17. Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytorreductive surgery and perioperative intraperitoneal chemotherapy for pseudomixoma peritonei. Ann Surg Oncol. 2007;14:484–92.

    Article  PubMed  Google Scholar 

  18. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.

    Article  PubMed  Google Scholar 

  19. Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytorreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18:827–34.

    Article  CAS  PubMed  Google Scholar 

  20. Helm CW. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist. 2009;14:683–94.

    Article  CAS  PubMed  Google Scholar 

  21. Muñoz-Casares FC, Rufián S, Rubio MJ, et al. Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals. Clin Transl Oncol. 2007;9:652–62.

    Article  PubMed  Google Scholar 

  22. Cascales PA, Gil J, Galindo PJ, Machado F, Frutos IM, Paricio PP. Heterogeneity in patients and methods. A problem for hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol. 2011;158:361–2.

    Article  CAS  PubMed  Google Scholar 

  23. Tentes AA, Tripsiannis G, Markakidis SK, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol. 2003;29:69–73.

    Article  PubMed  Google Scholar 

  24. National Cancer Institute. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v3.0 (CTCAE). 2013. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 10 June 2013.

  25. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:265–74.

    Article  PubMed  Google Scholar 

  26. Al Rawahi T, Lopes AD, Bristow RE, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev 2013;2:CD008765.

  27. Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13:1702.

    Article  PubMed  Google Scholar 

  28. Sugarbaker PH. Peritoneal carcinomatosis: natural history and rational therapeutic interventions using intraperitoneal chemotherapy. Cancer Treat Res. 1996;81:149–68.

    Article  CAS  PubMed  Google Scholar 

  29. Sugarbaker PH. It’s what the surgeon doesn’t see that kills the patient. J Nippon Med Sch. 2000;67:5–8.

    Article  CAS  PubMed  Google Scholar 

  30. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol. 2000; 78:269–74.

    Article  CAS  PubMed  Google Scholar 

  31. Berman ML. Future directions in the surgical management of ovarian cancer. Gynecol Oncol. 2003;90:S33–9.

    Article  PubMed  Google Scholar 

  32. Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. J Clin Oncol. 2005;23:8802–11.

    Article  PubMed  Google Scholar 

  33. Chua TC, Robertson G, Liauw W, et al. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009;135:1637–45.

    Article  PubMed  Google Scholar 

  34. Deraco M, Baratti D, Laterza B, et al. Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur J Surg Oncol. 2011;37:4–9.

    Article  CAS  PubMed  Google Scholar 

  35. Mohamed F, Sugarbaker PH. Intraperitoneal taxanes. Surg Oncol Clin N Am. 2003;12:825–33.

    Article  PubMed  Google Scholar 

  36. Bae JH, Lee JM, Ryu KS, et al. Treatment of ovarian cancer with paclitaxel-or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol. 2007;106:193–200.

    Article  CAS  PubMed  Google Scholar 

  37. Muñoz-Casares FC, Rufián S, Rubio MJ, et al. The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol. 2009;11:753–9.

    Article  PubMed  Google Scholar 

  38. Bouquet W, Deleye S, Staelens S, et al. Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model. Pharm Res. 2011;28:1653–60.

    Article  CAS  PubMed  Google Scholar 

  39. Hyperthermic intra-peritoneal chemotherapy (HIPEC) in relapse ovarian cancer treatment (CHIPOR): ClinicalTrials.gov identifier: NCT01376752. www.clinicaltrials.gov/ct2/show/NCT01376752.

  40. Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) in Ovarian Cancer Recurrence (HORSE): ClinicalTrials.gov identifier: NCT01539785. www.clinicaltrials.gov/ct2/show/NCT01539785.

Download references

Disclosure

None.

Author information

Authors and Affiliations

  1. Unidad De Cirugía De La Carcinomatosis Peritoneal, Departamento De Cirugía General, Virgen De La Arrixaca University Hospital, IMIB Arrixaca, Murcia, Spain

    Pedro Antonio Cascales-Campos MD, PhD, J. Gil MD, PhD, E. Gil MD, A. González-Gil MD, V. López MD, J. Ruiz-Pardo MD & P. Parrilla MD, PhD

  2. Departamento De Oncología Médica, Virgen De La Arrixaca University Hospital, IMIB Arrixaca, Murcia, Spain

    E. Feliciangeli MD

  3. Unidad De Ginecología Oncológica, Departamento De Ginecología y Obstetricia, Virgen De La Arrixaca University Hospital, IMIB Arrixaca, Murcia, Spain

    A. Nieto MD, PhD & J. J. Parrilla MD, PhD

Authors
  1. Pedro Antonio Cascales-Campos MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Gil MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Feliciangeli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Gil MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. González-Gil MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. López MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Ruiz-Pardo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Nieto MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. J. Parrilla MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P. Parrilla MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pedro Antonio Cascales-Campos MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cascales-Campos, P.A., Gil, J., Feliciangeli, E. et al. The Role of Hyperthermic Intraperitoneal Chemotherapy Using Paclitaxel in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer Patients with Microscopic Residual Disease after Cytoreduction. Ann Surg Oncol 22, 987–993 (2015). https://doi.org/10.1245/s10434-014-4049-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-4049-z

Keywords

Search

Navigation